{"created":"2023-06-19T09:12:55.881667+00:00","id":24853,"links":{},"metadata":{"_buckets":{"deposit":"dc7ba920-a3a7-4741-9b56-ec3c0159feba"},"_deposit":{"created_by":1,"id":"24853","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"24853"},"status":"published"},"_oai":{"id":"oai:kumadai.repo.nii.ac.jp:00024853","sets":["413:443"]},"author_link":["111949","111943","111947","111929","111950","98305","111948","111933","111934","111945","111931","111932","111930","111946","111927","111944"],"item_16_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-07-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"163","bibliographicPageStart":"157","bibliographicVolumeNumber":"90","bibliographic_titles":[{"bibliographic_title":"Clinical Pharmacology and Therapeutics"}]}]},"item_16_creator_3":{"attribute_name":"別言語の著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"山川, 裕司"}],"nameIdentifiers":[{"nameIdentifier":"111943","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"濱田, 哲暢"}],"nameIdentifiers":[{"nameIdentifier":"111944","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"首藤, 剛"}],"nameIdentifiers":[{"nameIdentifier":"111945","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"結城, 美里"}],"nameIdentifiers":[{"nameIdentifier":"111946","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"内田, 隆"}],"nameIdentifiers":[{"nameIdentifier":"111947","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"甲斐, 広文"}],"nameIdentifiers":[{"nameIdentifier":"111948","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"川口, 辰哉"}],"nameIdentifiers":[{"nameIdentifier":"111949","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"齋藤, 秀之"}],"nameIdentifiers":[{"nameIdentifier":"111950","nameIdentifierScheme":"WEKO"}]}]},"item_16_description_17":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_16_description_46":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"論文(Article)","subitem_description_type":"Other"}]},"item_16_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"The purpose of this study was to explore the role of the organic-anion transporting polypeptide (OATP) 1A2 that is encoded by SLCO1A2, in the cellular uptake of the BCR-ABL tyrosine kinase inhibitor imatinib, and the relationship between SLCO1A2 polymorphisms and the pharmacokinetics of imatinib in chronic myeloid leukemia (CML) patients. Imatinib uptake was significantly enhanced in OATP1A2-transfected human embryonic kidney (HEK)293 cells (P=0.002). Naringin, an OATP1A2 inhibitor, decreased the transport of imatinib in OATP1A2-transfected HEK293, the human intestinal cell line Caco-2, and the CML cell line K562 cells. Linkage disequilibrium was found between the SLCO1A2 -1105G>A and -1032G>A genotypes in 34 CML patients and 100 healthy subjects. Imatinib clearance of CML patients was influenced by the SLCO1A2 -1105G>A/-1032G>A genotype (P=0.075) and the SLCO1A2 -361GG genotype (P=0.005). These findings suggest that imatinib is transported into cells by OATP1A2, and that SLCO1A2 polymorphisms significantly affect imatinib pharmacokinetics.","subitem_description_type":"Other"}]},"item_16_description_77":{"attribute_name":"URL","attribute_value_mlt":[{"subitem_description":"http://www.nature.com/clpt/journal/v90/n1/full/clpt2011102a.html","subitem_description_type":"Other"}]},"item_16_publisher_36":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nature Publishing Group"}]},"item_16_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1038/clpt.2011.102","subitem_relation_type_select":"DOI"}}]},"item_16_relation_16":{"attribute_name":"情報源(ISSN)","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"00099236"}]}]},"item_16_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2011 American Society for Clinical Pharmacology and Therapeutics"}]},"item_16_subject_20":{"attribute_name":"日本十進分類法","attribute_value_mlt":[{"subitem_subject":"499","subitem_subject_scheme":"NDC"}]},"item_16_text_18":{"attribute_name":"形態","attribute_value_mlt":[{"subitem_text_value":"218180 bytes"}]},"item_16_text_47":{"attribute_name":"資源タイプ・ローカル","attribute_value_mlt":[{"subitem_text_value":"雑誌掲載論文"}]},"item_16_text_48":{"attribute_name":"資源タイプ・NII","attribute_value_mlt":[{"subitem_text_value":"Journal Article"}]},"item_16_text_49":{"attribute_name":"資源タイプ・DCMI","attribute_value_mlt":[{"subitem_text_value":"text"}]},"item_16_text_50":{"attribute_name":"資源タイプ・ローカル表示コード","attribute_value_mlt":[{"subitem_text_value":"01"}]},"item_16_version_type_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yamakawa, Yuji"}],"nameIdentifiers":[{"nameIdentifier":"111927","nameIdentifierScheme":"WEKO"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"濱田, 哲暢","creatorNameLang":"ja"},{"creatorName":"ハマダ, アキノブ","creatorNameLang":"ja-Kana"},{"creatorName":"Hamada, Akinobu","creatorNameLang":"en"}],"familyNames":[{"familyName":"濱田","familyNameLang":"ja"},{"familyName":"ハマダ","familyNameLang":"ja-Kana"},{"familyName":"Hamada","familyNameLang":"en"}],"givenNames":[{"givenName":"哲暢","givenNameLang":"ja"},{"givenName":"アキノブ","givenNameLang":"ja-Kana"},{"givenName":"Akinobu","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"98305","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shuto, Tsuyoshi"}],"nameIdentifiers":[{"nameIdentifier":"111929","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yuki, Misato"}],"nameIdentifiers":[{"nameIdentifier":"111930","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Uchida, Takashi"}],"nameIdentifiers":[{"nameIdentifier":"111931","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kai, Hirofumi"}],"nameIdentifiers":[{"nameIdentifier":"111932","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kawaguchi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"111933","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saito, Hideyuki"}],"nameIdentifiers":[{"nameIdentifier":"111934","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-03-02"}],"displaytype":"detail","filename":"CPT_90_1_157–163.pdf","filesize":[{"value":"218.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"CPT_90_1_157–163.pdf","url":"https://kumadai.repo.nii.ac.jp/record/24853/files/CPT_90_1_157–163.pdf"},"version_id":"3adb48ae-dae7-41ba-8cb7-c4d9fb9b2ec6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"imatinib","subitem_subject_scheme":"Other"},{"subitem_subject":"SLCO1A2","subitem_subject_scheme":"Other"},{"subitem_subject":"polymorphisms","subitem_subject_scheme":"Other"},{"subitem_subject":"pharmacogenetics","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia"}]},"item_type_id":"16","owner":"1","path":["443"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-01-27"},"publish_date":"2012-01-27","publish_status":"0","recid":"24853","relation_version_is_last":true,"title":["Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-09-14T07:09:02.655915+00:00"}